tiprankstipranks
Trending News
More News >
Immuneering (IMRX)
NASDAQ:IMRX
US Market

Immuneering (IMRX) Income Statement

Compare
649 Followers

Immuneering Income Statement

Last quarter (Q4 2025), Immuneering's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q4, Immuneering's net income was $-11.58M. See Immuneering’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Dec 23Dec 22Dec 21
Total Revenue
$ 0.00$ 0.00$ 0.00$ 316.95K$ 2.08M
Gross Profit
$ -698.89K$ 0.00$ 0.00$ 158.83K$ 926.89K
Operating Expenses
$ 58.68M$ 64.07M$ 58.41M$ 51.90M$ 34.81M
Depreciation and Amortization
$ 698.89K$ 385.07K$ 352.08K$ 277.25K$ 159.07K
EBITDA
$ -58.68M$ -63.69M$ -58.06M$ -51.47M$ -33.73M
Operating Income
$ -59.38M$ -64.07M$ -58.41M$ -51.74M$ -33.89M
Other Income/Expenses
$ 3.35M$ 3.03M$ 4.94M$ 1.23M$ 42.83K
Pretax Income
$ -56.02M$ -61.04M$ -53.47M$ -50.51M$ -33.84M
Net Income
$ -56.02M$ -61.04M$ -53.47M$ -50.51M$ -33.54M
Per Share Metrics
Basic EPS
$ -1.27$ -2.04$ -1.88$ -1.87$ -1.27
Diluted EPS
$ -1.27$ -2.04$ -1.88$ -1.87$ -1.27
Weighted Average Shares Outstanding
44.01M 29.98M 28.42M 26.39M 26.32M
Weighted Average Shares Outstanding (Diluted)
44.01M 29.98M 28.42M 26.39M 26.32M
Currency in USD

Immuneering Earnings and Revenue History